KR20250004869A - 경부 이상긴장증의 치료 - Google Patents

경부 이상긴장증의 치료 Download PDF

Info

Publication number
KR20250004869A
KR20250004869A KR1020247039344A KR20247039344A KR20250004869A KR 20250004869 A KR20250004869 A KR 20250004869A KR 1020247039344 A KR1020247039344 A KR 1020247039344A KR 20247039344 A KR20247039344 A KR 20247039344A KR 20250004869 A KR20250004869 A KR 20250004869A
Authority
KR
South Korea
Prior art keywords
modified bont
bont
administered
scalene
capitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039344A
Other languages
English (en)
Korean (ko)
Inventor
니콜라에 그리고레
로랑 폰즈
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Publication of KR20250004869A publication Critical patent/KR20250004869A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247039344A 2022-04-29 2023-03-23 경부 이상긴장증의 치료 Pending KR20250004869A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2206353.1A GB202206353D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia
GB2206353.1 2022-04-29
PCT/GB2023/050742 WO2023209326A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia

Publications (1)

Publication Number Publication Date
KR20250004869A true KR20250004869A (ko) 2025-01-08

Family

ID=81943814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247039344A Pending KR20250004869A (ko) 2022-04-29 2023-03-23 경부 이상긴장증의 치료

Country Status (9)

Country Link
US (1) US20250302928A1 (https=)
EP (1) EP4514378A1 (https=)
JP (1) JP2025514275A (https=)
KR (1) KR20250004869A (https=)
CN (1) CN119110728A (https=)
AU (1) AU2023262641A1 (https=)
CA (1) CA3245899A1 (https=)
GB (1) GB202206353D0 (https=)
WO (1) WO2023209326A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
CA2758274C (en) 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3162894B1 (en) 2011-05-19 2024-01-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
JP2024534384A (ja) * 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ

Also Published As

Publication number Publication date
GB202206353D0 (en) 2022-06-15
JP2025514275A (ja) 2025-05-02
CA3245899A1 (en) 2023-11-02
AU2023262641A1 (en) 2024-10-10
CN119110728A (zh) 2024-12-10
WO2023209326A1 (en) 2023-11-02
US20250302928A1 (en) 2025-10-02
EP4514378A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
US20250302928A1 (en) Treatment of cervical dystonia
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
US20250177278A1 (en) Treatment of upper facial lines
HK40114696A (zh) 颈肌张力障碍的治疗
KR20250004871A (ko) 사지 경직의 치료
WO2025093844A1 (en) Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
HK40114374A (zh) 修饰的bont/a用於颈肌张力障碍的治疗
HK40118896A (zh) 上面部纹的治疗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000